These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 20669252)

  • 21. Spontaneous unwelcome orgasms due to pramipexole and ropinirole.
    Kaut O; Asmus F; Paus S
    Mov Disord; 2012 Sep; 27(10):1327-8. PubMed ID: 22903628
    [No Abstract]   [Full Text] [Related]  

  • 22. Exercise dependence induced by pramipexole in Parkinson's Disease-a case report.
    Vitale C; Santangelo G; Verde F; Amboni M; Sorrentino G; Grossi D; Barone P
    Mov Disord; 2010 Dec; 25(16):2893-4. PubMed ID: 20687190
    [No Abstract]   [Full Text] [Related]  

  • 23. Deprenyl in Parkinson's disease.
    Korczyn AD; Nisipeanu P
    Ann Neurol; 1996 Aug; 40(2):268-9. PubMed ID: 8773617
    [No Abstract]   [Full Text] [Related]  

  • 24. [Pathological gambling behavior in a patient with Parkinson's disease treated with levodopa and bromocriptine].
    Montastruc JL; Schmitt L; Bagheri H
    Rev Neurol (Paris); 2003 Apr; 159(4):441-3. PubMed ID: 12773874
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Treatment of parkinsonism and legal capacity].
    Wallesch CW
    Fortschr Neurol Psychiatr; 2011 Aug; 79(8):441. PubMed ID: 21809256
    [No Abstract]   [Full Text] [Related]  

  • 26. Pathological gambling in Parkinson's disease.
    O'Sullivan SS; Lees AJ
    Lancet Neurol; 2007 May; 6(5):384-6. PubMed ID: 17434085
    [No Abstract]   [Full Text] [Related]  

  • 27. Managing pathological gambling in Parkinson's disease with enteral levodopa/carbidopa infusions.
    Gerschlager W; Bloem BR
    Mov Disord; 2009 Sep; 24(12):1858-60. PubMed ID: 19514056
    [No Abstract]   [Full Text] [Related]  

  • 28. [Neurobiology of pathological gambling].
    Kaasinen V; Halme J; Alho H
    Duodecim; 2009; 125(19):2075-83. PubMed ID: 19938411
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Delusional Parasitosis as a Treatment Complication of Parkinson Disease.
    Ojeda-López C; Aguilar-Venegas LC; Tapia-Orozco M; Cervantes-Arriaga A; Rodríguez-Violante M
    Psychosomatics; 2015; 56(6):696-9. PubMed ID: 26481963
    [No Abstract]   [Full Text] [Related]  

  • 30. Administration of selegiline is not associated with visual hallucinations in advanced Parkinson's disease patients.
    Papapetropoulos S; Argyriou AA
    Parkinsonism Relat Disord; 2005 Jun; 11(4):265-6; author reply 267. PubMed ID: 15878591
    [No Abstract]   [Full Text] [Related]  

  • 31. Burden of cardiovascular diseases in elderly with Parkinson's disease who start a dopamine agonist agent.
    Trifirò G; Morgante L; Tari M; Arcoraci V; Savica R
    J Am Geriatr Soc; 2008 Feb; 56(2):371-3. PubMed ID: 18251828
    [No Abstract]   [Full Text] [Related]  

  • 32. Current status of selegiline as a neuroprotective agent in Parkinson's disease.
    Olanow CW; Mytilineou C; Tatton W
    Mov Disord; 1998; 13 Suppl 1():55-8. PubMed ID: 9613720
    [No Abstract]   [Full Text] [Related]  

  • 33. Text messaging as a new compulsive behavior in a patient with Parkinson's disease.
    Ertem DH; Maner F; Koksal A
    Psychiatry Clin Neurosci; 2013 Feb; 67(2):126-7. PubMed ID: 23438166
    [No Abstract]   [Full Text] [Related]  

  • 34. Hypersexuality and paraphilia induced by selegiline in Parkinson's disease: report of 2 cases.
    Shapiro MA; Chang YL; Munson SK; Okun MS; Fernandez HH
    Parkinsonism Relat Disord; 2006 Sep; 12(6):392-5. PubMed ID: 16730214
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Medications used to treat Parkinson's disease and the risk of gambling.
    Imamura A; Geda YE; Slowinski J; Wszolek ZK; Brown LA; Uitti RJ
    Eur J Neurol; 2008 Apr; 15(4):350-4. PubMed ID: 18312405
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Therapeutic results with a new ergoline derivate (8-alpha-amino-ergoline, CU 32-085) in parkinsonian patients.
    Schneider E; Hubener K; Fischer PA
    Adv Neurol; 1984; 40():527-9. PubMed ID: 6695631
    [No Abstract]   [Full Text] [Related]  

  • 37. Clozapine in the treatment of psychosis in Parkinson's disease.
    Friedman JH; Lannon MC
    Neurology; 1989 Sep; 39(9):1219-21. PubMed ID: 2771073
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ondansetron, a 5-HT3 antagonist for visual hallucinations and paranoid delusional disorder associated with chronic L-DOPA therapy in advanced Parkinson's disease.
    Zoldan J; Friedberg G; Weizman A; Melamed E
    Adv Neurol; 1996; 69():541-4. PubMed ID: 8615178
    [No Abstract]   [Full Text] [Related]  

  • 39. Pramipexole-related chronic lower limb oedema in a patient with Parkinson's disease.
    Zavala JA; Munhoz RP; Teive HA
    J Clin Neurosci; 2012 Sep; 19(9):1298-9. PubMed ID: 22721884
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Possible serotonin syndrome arising from an interaction between nortriptyline and selegiline in a lady with parkinsonism.
    Hinds NP; Hillier CE; Wiles CM
    J Neurol; 2000 Oct; 247(10):811. PubMed ID: 11127542
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.